Premium
A phase II trial of carboplatin in untreated patients with extensive stage small cell lung cancer
Author(s) -
Pallares Cinta,
Izquierdo Miguel Angel,
Paredes Alfredo,
Sagarra Alberto Fernandez,
de Andrés Luis,
José López López Juan
Publication year - 1991
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19910701)68:1<40::aid-cncr2820680108>3.0.co;2-y
Subject(s) - medicine , carboplatin , neutropenia , toxicity , gastroenterology , lung cancer , platelet , hemoglobin , chemotherapy , confidence interval , leukopenia , surgery , cisplatin
Abstract Twenty‐five untreated patients with extensive stage small cell lung cancer (ESSCLC) were treated with carboplatin (CBDCA) (500 mg/m 2 ) given as a 24‐hour infusion every 21 days. Thirteen patients responded for an overall response rate of 52% (95% confidence limits, 32% to 72%) with 3 complete responses (CR) (12%; 95% confidence limits, 0% to 25%). The median duration of response was 4.5 months. The median survival time was 8 months with three long‐term survivors (12%) at 27, 33, and 43 months from the start of CBDCA treatment. Ninety‐two courses of CBDCA were administered and one treatment‐related death occurred. The main toxicity was myelosuppression. Grade 3 or 4 hematologic toxicity (hemoglobin level, < 8 g/dl; granulocyte count, < 1900/μl; and platelet count, < 49,000/μl) was observed as follows: neutropenia in 7 courses (8%) and in 7 patients (28%), decreased hemoglobin level in 13 courses (15%) and in 7 patients (28%), and decreased platelet count in 10 courses (11%) all Grade 3 and in 8 patients (32%). This study demonstrates that at this dose and schedule CBDCA is a highly active drug in ESSCLC and it has tolerable toxicity.